The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Pharmacy leaders have issued a warning over the online sale of weight-loss jabs insisting there is still a risk to patient ...

If you can’t or don’t want to take Ozempic, your healthcare professional may recommend a different medication. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist medication that ...

FreshSplash/Getty Images Researchers report that GLP-1 drugs prescribed for weight loss, like Ozempic and Mounjaro, may improve cognition and lower dementia and cardiovascular disease risk.

Semaglutide (known by its brandname Ozempic) has gained widespread attention ... data on its risks and benefits for those with type 1 diabetes, new research offers promising insights.

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

Until you consider a Morgan Stanley projection that says by 2035, 24 million people will be taking Ozempic, Wegovy, or another GLP-1. Which makes sense. A study published in the Journal of the ...

A first randomized clinical trial shows that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss and lower insulin requirements. Semaglutide (known by its ...